TaiMed Biologics Inc.(TW:4147)
NT$61.90+1.60 (+2.65%)
TW:4147
TaiMed Biologics Inc. financials statements
NT$61.90
At close:+1.60 (+2.65%)
TaiMed Biologics Inc. (4147) Ratios
TaiMed Biologics Inc. Ratios
TW:4147's free cash flow for Q2 2026 was NT$32.53M. For the 2026 fiscal year, TW:4147's free cash flow was decreased by NT$-26.35M and operating cash flow was NT$58.88M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 13.11 | 25.18 | 5.96 | 6.56 | 10.37 |
| Quick Ratio | 7.59 | 13.54 | 2.44 | 2.37 | 5.18 |
| Cash Ratio | 3.54 | 4.31 | 0.69 | 0.83 | 2.45 |
| Solvency Ratio | -0.02 | -0.05 | -0.03 | -0.09 | -0.19 |
| Operating Cash Flow Ratio | 0.75 | -2.82 | -0.07 | -1.83 | -0.94 |
| Short-Term Operating Cash Flow Coverage | 6.87 | -13.93 | -0.11 | -2.82 | 4.09 |
| Net Current Asset Value | NT$ 2.37B | NT$ 2.42B | NT$ 823.56M | NT$ 778.80M | NT$ 665.72M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.10 | 0.10 | 0.19 | 0.19 | 0.12 |
| Debt-to-Equity Ratio | 0.13 | 0.13 | 0.29 | 0.28 | 0.19 |
| Debt-to-Capital Ratio | 0.11 | 0.11 | 0.23 | 0.22 | 0.16 |
| Long-Term Debt-to-Capital Ratio | 0.10 | 0.10 | 0.16 | 0.16 | 0.15 |
| Financial Leverage Ratio | 1.25 | 1.24 | 1.52 | 1.51 | 1.57 |
| Debt Service Coverage Ratio | -1.08 | -0.89 | -0.10 | -0.50 | 7.11 |
| Interest Coverage Ratio | -18.17 | -20.01 | -11.22 | -25.66 | -62.26 |
| Debt to Market Cap | 0.03 | 0.02 | 0.03 | 0.04 | 0.03 |
| Interest Debt Per Share | 1.83 | 2.00 | 3.03 | 3.03 | 2.25 |
| Net Debt to EBITDA | 9.73 | 1.62 | -20.31 | -4.79 | -0.05 |
| Profitability Margins | |||||
| Gross Profit Margin | 42.44% | 34.62% | 45.80% | 38.31% | 20.31% |
| EBIT Margin | -31.84% | -31.01% | -36.60% | -46.04% | -112.10% |
| EBITDA Margin | -6.81% | -5.83% | -5.00% | -18.25% | -74.21% |
| Operating Profit Margin | -31.84% | -41.34% | -33.80% | -46.04% | -112.10% |
| Pretax Profit Margin | -27.44% | -33.08% | -39.61% | -47.83% | -113.91% |
| Net Profit Margin | -27.44% | -33.08% | -39.61% | -49.62% | -115.71% |
| Continuous Operations Profit Margin | -27.44% | -33.08% | -39.61% | -47.83% | -113.91% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 103.75% | 101.58% |
| EBT Per EBIT | 86.20% | 80.01% | 117.19% | 103.90% | 101.61% |
| Return on Assets (ROA) | -3.49% | -4.04% | -5.00% | -6.81% | -10.38% |
| Return on Equity (ROE) | -4.35% | -5.02% | -7.59% | -10.29% | -16.26% |
| Return on Capital Employed (ROCE) | -4.27% | -5.19% | -4.71% | -6.87% | -10.57% |
| Return on Invested Capital (ROIC) | -4.24% | -5.15% | -4.42% | -6.50% | -10.69% |
| Return on Tangible Assets | -3.84% | -4.53% | -5.96% | -8.27% | -12.62% |
| Earnings Yield | -1.00% | -0.88% | -0.94% | -1.54% | -2.65% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.80 | 5.70 | 2.61 | 4.55 | 2.14 |
| Payables Turnover | 4.34 | 528.39 | 19.75 | 3902.21 | 2.69 |
| Inventory Turnover | 0.25 | 0.25 | 0.21 | 0.25 | 0.28 |
| Fixed Asset Turnover | 0.74 | 0.71 | 0.54 | 0.59 | 0.41 |
| Asset Turnover | 0.13 | 0.12 | 0.13 | 0.14 | 0.09 |
| Working Capital Turnover Ratio | 0.19 | 0.24 | 0.27 | 0.29 | 0.19 |
| Cash Conversion Cycle | 1442.77 | 1499.27 | 1861.47 | 1532.75 | 1328.88 |
| Days of Sales Outstanding | 76.11 | 64.00 | 140.02 | 80.22 | 170.56 |
| Days of Inventory Outstanding | 1450.68 | 1435.96 | 1739.94 | 1452.63 | 1294.12 |
| Days of Payables Outstanding | 84.02 | 0.69 | 18.48 | 0.09 | 135.80 |
| Operating Cycle | 1526.79 | 1499.96 | 1879.95 | 1532.85 | 1464.67 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.69 | -1.42 | -0.10 | -2.36 | -0.83 |
| Free Cash Flow Per Share | 0.61 | -1.49 | -0.13 | -2.38 | -0.88 |
| Dividend Paid and CapEx Coverage Ratio | 8.43 | -19.61 | -4.16 | -127.12 | -15.58 |
| Capital Expenditure Coverage Ratio | 8.43 | -19.61 | -4.16 | -127.12 | -15.58 |
| Operating Cash Flow Coverage Ratio | 0.39 | -0.73 | -0.03 | -0.79 | -0.37 |
| Operating Cash Flow to Sales Ratio | 0.31 | -0.62 | -0.05 | -1.07 | -0.51 |
| Free Cash Flow Yield | 1.00% | -1.73% | -0.15% | -3.37% | -1.24% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -100.33 | -114.67 | -106.38 | -67.33 | -37.75 |
| Price-to-Sales (P/S) Ratio | 27.53 | 37.80 | 42.14 | 32.15 | 43.70 |
| Price-to-Book (P/B) Ratio | 4.36 | 5.73 | 8.08 | 6.67 | 6.14 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 99.91 | -57.82 | -652.64 | -29.68 | -80.37 |
| Price-to-Operating Cash Flow Ratio | 88.06 | -60.77 | -809.47 | -29.91 | -85.53 |
| Price-to-Earnings Growth (PEG) Ratio | 5.37 | 44.15 | 3.99 | 1.54 | -0.24 |
| Enterprise Value Multiple | -394.33 | -646.88 | -862.38 | -180.98 | -58.94 |
| Enterprise Value | 16.43B | 23.01B | 21.22B | 18.59B | 18.09B |
| EV to EBITDA | -394.33 | -646.88 | -862.38 | -180.98 | -58.94 |
| EV to Sales | 26.87 | 37.71 | 43.16 | 33.03 | 43.74 |
| EV to Free Cash Flow | 97.51 | -57.68 | -668.38 | -30.48 | -80.44 |
| EV to Operating Cash Flow | 85.94 | -60.62 | -828.99 | -30.72 | -85.60 |
| Tangible Book Value Per Share | 12.42 | 12.99 | 7.67 | 7.77 | 8.28 |
| Shareholders’ Equity Per Share | 14.03 | 15.00 | 10.14 | 10.60 | 11.49 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | -0.04 | -0.02 |
| Revenue Per Share | 2.22 | 2.27 | 1.94 | 2.20 | 1.62 |
| Net Income Per Share | -0.61 | -0.75 | -0.77 | -1.09 | -1.87 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.04 | 1.02 |
| Interest Burden | 0.86 | 1.07 | 1.08 | 1.04 | 1.02 |
| Research & Development to Revenue | 0.62 | 0.64 | 0.60 | 0.59 | 1.11 |
| SG&A to Revenue | 0.12 | 0.12 | 0.20 | 0.13 | 0.27 |
| Stock-Based Compensation to Revenue | 0.01 | 0.04 | 0.02 | 0.02 | 0.02 |
| Income Quality | -1.14 | 1.88 | 0.13 | 2.25 | 0.45 |
Currency in TWD
